查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1971060

生物偶聯市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、應用、地區和競爭對手分類，2021-2031年

Bioconjugation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Reagents & Kits, Labels, Others), By Application (Therapeutics, Research & Development, Diagnostics), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球生物偶聯市場預計將從 2025 年的 17.9 億美元成長到 2031 年的 26.1 億美元，複合年成長率達到 6.49%。

生物偶聯技術是一種將生物分子（例如抗體）與其他物質進行化學結合，從而形成穩定的偶聯物，以改善診斷和治療效果的技術。該市場的主要驅動力是慢性疾病（尤其是癌症）發生率的上升，這推動了對精準標靶治療（例如抗體藥物複合體(ADC)）的需求。此外，連接子技術的進步提高了藥物的療效和穩定性，進一步加速了該技術在業界的應用。為了凸顯這一趨勢，抗體協會報告稱，到 2024 年，ADC 將佔癌症適應症臨床抗體研發管線的約 20%。

市場概覽
預測期 2027-2031
市場規模：2025年 17.9億美元
市場規模：2031年 26.1億美元
複合年成長率：2026-2031年 6.49%
成長最快的細分市場 試劑和試劑盒
最大的市場 北美洲

儘管市場呈現成長態勢，但由於生物偶聯產品生產固有的高成本和技術挑戰，仍面臨許多障礙。開發這些混合療法需要專門的基礎設施和技術專長來維持產品的一致性並避免聚集，而這些要求極大地限制了產能。因此，複雜的供應鏈以及關於安全性和有效性的嚴格監管標準阻礙了快速規模化生產，從而為中小型製藥公司設定了進入門檻。

市場促進因素

生物製藥和先進藥物遞送系統研發投入的不斷成長是全球生物偶聯市場的主要驅動力。製藥公司競相獲取在研產品，以滿足日益成長的癌症患者需求。核准治療方法的高商業性回報證明了這項巨額資本投資的合理性，也彌補了領先研發成本的不足。例如，根據 Pharmaphorum 2025 年 11 月報道，“阿斯特捷利康第三季銷售額創下 150 億美元的紀錄”，Astra Zeneca的癌症治療產品銷售額成長 18% 至 66.4 億美元，主要得益於其抗體藥物複合體Enhart 的成功。這種潛力正在推動許可協議的激增。根據 Express Pharma 2025 年 5 月報告，中國生物製藥公司單株抗體和抗體藥物偶聯物 (ADC) 相關授權協議的總價值達到 300 億美元，這表明全球對創新候選藥物的競爭異常激烈。

同時，生技產業越來越依賴專業的合約研發生產機構（CDMO）來克服技術生產障礙。生物偶聯物的開發需要複雜的製程流程，涉及強效細胞毒性有效載荷和精確的連接子化學，這些能力往往超出生物技術公司的內部資源。因此，創新公司傾向將這些關鍵任務外包以加速研發。這一趨勢在藥明康德於2025年8月發布的「2025會計年度中期業績報告」中得到了充分體現，該報告顯示，在對一體化抗體偶聯藥物（ADC）和生物偶聯物生產服務的強勁需求推動下，公司營收同比成長62.2%。

市場挑戰

全球生物偶聯物市場的發展受到此類混合療法生產過程中極高的技術複雜性和高成本的顯著限制。生產穩定的生物偶聯物需要高度專業的基礎設施，能夠在嚴格的防護通訊協定下安全地管理生物材料和有毒有效載荷。這種雙重處理能力的要求導致合格生產設施短缺，使得製造商難以有效率地擴大生產規模以滿足不斷成長的市場需求。

因此，內部生產能力不足導致企業更加依賴分散的供應鏈，進而帶來產品品質一致性和交付時間的風險。根據製藥、化學及相關技術協會（DCAT）預測，到2024年，約70%的抗體藥物複合體（ADC）生產將外包。這是因為研發公司缺乏足夠的內部生產能力。這種對第三方供應商的依賴增加了生產成本，延長了研發週期，進而減緩了市場擴張速度，阻礙了資金有限的中小型製藥公司進入市場。

市場趨勢

全球生物偶聯市場的一項變革性趨勢是抗體藥物複合體(ADC) 的應用範圍從腫瘤領域擴展到非癌症疾病，尤其是自體免疫疾病。研發人員正積極利用生物偶聯技術遞送免疫調節有效載荷，透過恢復免疫耐受而非誘導細胞死亡，為慢性疾病提供更精準的治療方案。這種多元化發展吸引了大量投資。正如《製藥高管》(Pharmaceutical Executive) 2025 年 10 月發表的一篇報導“聚焦抗體抗體藥物複合體進展的製藥合作”的文章報道，賽諾菲已與 EVOQ Therapeutics 達成合作，投資高達 5 億美元，利用奈米盤技術開發用於治療類風濕性關節炎和狼瘡等自體免疫關節炎的生物性關節炎。

同時，放射免疫偶聯物和治療診斷學領域正經歷快速成長，該領域將放射性同位素與抗體偶聯，使其在診斷和治療中發揮雙重作用。這種方法使臨床醫生能夠在進行標靶放射治療前對疾病負荷進行成像，從而顯著提高治療的個人化程度。該領域的商業性潛力正推動著尋求下一代放射性配體研發管線的跨國公司積極進行收購。例如，根據《放射學商業》（Radiology Business）2025年6月刊報道，百時美施貴寶公司同意支付超過3.5億美元的領先，從Philochem公司收購一種用於前列腺癌的臨床階段成像放射性藥物的全球獨家權益。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球生物偶聯市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類別（試劑/試劑盒、標籤、其他）
    • 依應用領域（治療藥物、研發、診斷試劑）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美生物偶聯市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲生物偶聯市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區生物偶聯市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲生物偶聯市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲生物偶聯市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球生物偶聯市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • Sartorius AG
  • Abbvie, Inc.
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Catalent, Inc.
  • Becton, Dickinson and Company

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 28067

The Global Bioconjugation Market is projected to expand from USD 1.79 billion in 2025 to USD 2.61 billion by 2031, achieving a CAGR of 6.49%. Bioconjugation involves the chemical linking of a biomolecule, such as an antibody, with another substance to create a stable complex that offers improved diagnostic or therapeutic benefits. The primary driver of this market is the rising incidence of chronic diseases, especially cancer, which has fueled the demand for precise targeted treatments like antibody-drug conjugates (ADCs). Additionally, advancements in linker technologies that enhance drug efficacy and stability are further accelerating industry adoption. Highlighting this focus, The Antibody Society reported that in 2024, ADCs accounted for roughly 20% of the clinical antibody pipeline for cancer indications.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.79 Billion
Market Size 2031USD 2.61 Billion
CAGR 2026-20316.49%
Fastest Growing SegmentReagents & Kits
Largest MarketNorth America

Despite this growth, the market faces substantial obstacles due to the high costs and technical difficulties inherent in manufacturing bioconjugated products. Creating these hybrid therapies demands specialized infrastructure and technical expertise to maintain consistency and avoid aggregation, requirements that significantly restrict production capacity. Consequently, the complex supply chain, along with rigorous regulatory standards for safety and efficacy, impedes rapid scalability and creates barriers to entry for smaller pharmaceutical companies.

Market Driver

Increased R&D spending on biologics and advanced drug delivery systems is a major force propelling the Global Bioconjugation Market, as pharmaceutical firms race to secure pipeline assets addressing cancer prevalence. This heavy capital investment is justified by the high commercial returns of approved therapies, which validate the significant upfront development costs. For instance, in November 2025, Pharmaphorum reported in 'AZ's Q3 sales reach record $15bn' that AstraZeneca saw an 18% rise in oncology sales to $6.64 billion, largely driven by the success of the antibody-drug conjugate Enhertu. This potential has triggered a surge in licensing deals; according to Express Pharma in May 2025, the total value of deals for monoclonal antibodies and ADCs licensed from Chinese biopharma companies hit $30 billion, illustrating fierce global competition for innovative candidates.

Simultaneously, the industry is increasingly relying on specialized Contract Development and Manufacturing Organizations (CDMOs) to navigate technical production barriers. The development of bioconjugates requires complex processes involving potent cytotoxic payloads and precise linker chemistry, capabilities that often surpass the internal resources of biotech companies. As a result, innovators are outsourcing these critical tasks to speed up development. This trend is highlighted by WuXi XDC's August 2025 'Interim Results 2025' announcement, which reported a 62.2% year-over-year revenue jump attributed to strong demand for integrated ADC and bioconjugate manufacturing services.

Market Challenge

The Global Bioconjugation Market is significantly hindered by the extreme technical complexity and high costs involved in manufacturing these hybrid therapies. Producing stable bioconjugates necessitates highly specialized infrastructure capable of safely managing both biologic materials and toxic payloads under strict containment protocols. This requirement for dual-handling capabilities results in a shortage of qualified production facilities, making it difficult for manufacturers to scale operations efficiently to meet growing demand.

As a consequence, the lack of internal capacity creates a heavy dependence on a fragmented supply chain, introducing risks regarding product consistency and timing. According to the Drug, Chemical & Associated Technologies Association, approximately 70% of antibody-drug conjugate manufacturing was outsourced in 2024 because developers lacked sufficient in-house capabilities. This reliance on third-party vendors increases production costs and prolongs development timelines, effectively slowing market expansion and preventing smaller pharmaceutical entities with limited capital from entering the sector.

Market Trends

A transformative trend in the Global Bioconjugation Market is the expansion of antibody-drug conjugates (ADCs) beyond oncology into non-cancer indications, specifically autoimmune disorders. Developers are increasingly utilizing bioconjugation to deliver immunomodulatory payloads that restore immune tolerance rather than causing cell death, offering more precise treatment for chronic conditions. This diversification is attracting significant investment, as demonstrated in October 2025 when Pharmaceutical Executive reported in 'Pharma Collaborations Focused on Advancing Antibody-Drug Conjugates' that Sanofi formed a partnership worth up to $500 million with EVOQ Therapeutics to develop bioconjugates for autoimmune diseases like rheumatoid arthritis and lupus using nanodisc technology.

Concurrently, the market is seeing strong growth in radioimmunoconjugates and theranostic applications, which link radioisotopes to antibodies for dual diagnostic and therapeutic roles. This method allows clinicians to image disease burden before administering a targeted radioactive dose, greatly enhancing treatment personalization. The commercial potential of this segment is driving aggressive acquisitions by multinational firms seeking next-generation radioligand pipelines. For example, Radiology Business reported in June 2025 that Bristol Myers Squibb agreed to pay over $350 million upfront to license exclusive global rights for a clinical-stage prostate cancer imaging and radiopharmaceutical agent from Philochem.

Key Market Players

  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • Sartorius AG
  • Abbvie, Inc.
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Catalent, Inc.
  • Becton, Dickinson and Company

Report Scope

In this report, the Global Bioconjugation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bioconjugation Market, By Product

  • Reagents & Kits
  • Labels
  • Others

Bioconjugation Market, By Application

  • Therapeutics
  • Research & Development
  • Diagnostics

Bioconjugation Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bioconjugation Market.

Available Customizations:

Global Bioconjugation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bioconjugation Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Reagents & Kits, Labels, Others)
    • 5.2.2. By Application (Therapeutics, Research & Development, Diagnostics)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Bioconjugation Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bioconjugation Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Bioconjugation Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Bioconjugation Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application

7. Europe Bioconjugation Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Bioconjugation Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
    • 7.3.2. France Bioconjugation Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Bioconjugation Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Bioconjugation Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Bioconjugation Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application

8. Asia Pacific Bioconjugation Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Bioconjugation Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
    • 8.3.2. India Bioconjugation Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Bioconjugation Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Bioconjugation Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Bioconjugation Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application

9. Middle East & Africa Bioconjugation Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Bioconjugation Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Bioconjugation Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Bioconjugation Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application

10. South America Bioconjugation Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Bioconjugation Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Bioconjugation Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Bioconjugation Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Bioconjugation Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Danaher Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific Inc.
  • 15.3. Lonza Group Ltd.
  • 15.4. Merck KGaA
  • 15.5. Sartorius AG
  • 15.6. Abbvie, Inc.
  • 15.7. Bio-Rad Laboratories, Inc.
  • 15.8. Agilent Technologies, Inc.
  • 15.9. Catalent, Inc.
  • 15.10. Becton, Dickinson and Company

16. Strategic Recommendations

17. About Us & Disclaimer